Eisai

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Eisai and buy or sell other stocks, ETFs, and their options commission-free!

About ESALY

Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. 

CEO
Haruo Naito
CEOHaruo Naito
Employees
Employees
Headquarters
Tokyo, Tokyo
HeadquartersTokyo, Tokyo
Founded
1936
Founded1936
Employees
Employees

ESALY Key Statistics

Market cap
17.35B
Market cap17.35B
Price-Earnings ratio
25.50
Price-Earnings ratio25.50
Dividend yield
Dividend yield
Average volume
61.34K
Average volume61.34K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$9.22
52 Week high$9.22
52 Week low
$5.94
52 Week low$5.94

Stock Snapshot

With a market cap of 17.35B, Eisai(ESALY) trades at $61.51. The stock has a price-to-earnings ratio of 25.50.

Eisai(ESALY) stock opened on 2025-12-06 at —. The price climbed to — and dipped to —.

Eisai(ESALY) shares are trading with a volume of 0, against a daily average of 61.34K.

During the past year, Eisai(ESALY) stock moved between $5.94 at its lowest and $9.22 at its peak.

During the past year, Eisai(ESALY) stock moved between $5.94 at its lowest and $9.22 at its peak.

ESALY News

Nasdaq 3d
Eisai And Biogen Report Long-Term Benefits Of LEQEMBI In Early Alzheimer's Disease

(RTTNews) - Eisai Co., Ltd. and Biogen Inc. announced new findings on the continued and expanding benefit of LEQEMBI (lecanemab-irmb) maintenance treatment in e...

Eisai And Biogen Report Long-Term Benefits Of LEQEMBI In Early Alzheimer's Disease
TipRanks 3d
Eisai, Biogen say Leqembi data suggests potential to delay disease progression

Eisai (ESALY) and Biogen (BIIB) announced that the latest findings on time savings with continued treatment with humanized anti-soluble aggregated amyloid-beta...

Nasdaq 5d
Eisai : Etalanetug Demonstrates Reduction Of EMTBR-tau243 In Phase Ib/II Alzheimer's Study

(RTTNews) - Eisai Co., Ltd. announced new data on its anti-tau antibody etalanetug at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference. Etalane...

Eisai : Etalanetug Demonstrates Reduction Of EMTBR-tau243 In Phase Ib/II Alzheimer's Study
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.